|
|
| | M2e, human Basic information |
| Product Name: | M2e, human | | Synonyms: | M2e, human;L-Aspartic acid, L-seryl-L-leucyl-L-leucyl-L-threonyl-L-α-glutamyl-L-valyl-L-α-glutamyl-L-threonyl-L-prolyl-L-isoleucyl-L-arginyl-L-asparaginyl-L-α-glutamyl-L-tryptophylglycyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-asparaginyl-L-α-aspartyl-L-seryl-L-seryl- | | CAS: | 251359-24-7 | | MF: | C107H170N32O41S2 | | MW: | 2624.84 | | EINECS: | | | Product Categories: | | | Mol File: | 251359-24-7.mol |  |
| | M2e, human Chemical Properties |
| density | 1.59±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | M2e, human Usage And Synthesis |
| Uses | M2e, human, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A, which is a valid and versatile vaccine candidate to protect against any strain of human influenza A[1]. | | References | [1] De Filette M, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine. 2006 Nov 10;24(44-46):6597-601. DOI:10.1016/j.vaccine.2006.05.082 |
| | M2e, human Preparation Products And Raw materials |
|